KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 102 filers reported holding KALA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $7,000 | -12.5% | 29,800 | +10.0% | 0.00% | 0.0% |
| Q2 2022 | $8,000 | -74.2% | 27,100 | +19.4% | 0.00% | -66.7% |
| Q1 2022 | $31,000 | +55.0% | 22,700 | +37.6% | 0.00% | +50.0% |
| Q4 2021 | $20,000 | -82.3% | 16,500 | -61.6% | 0.00% | -77.8% |
| Q3 2021 | $113,000 | -30.2% | 42,996 | +40.5% | 0.01% | -35.7% |
| Q2 2021 | $162,000 | +3.8% | 30,596 | +31.9% | 0.01% | +16.7% |
| Q1 2021 | $156,000 | +13.0% | 23,196 | +13.7% | 0.01% | 0.0% |
| Q4 2020 | $138,000 | -0.7% | 20,396 | +9.7% | 0.01% | -52.0% |
| Q3 2020 | $139,000 | -1.4% | 18,596 | +38.3% | 0.02% | -7.4% |
| Q2 2020 | $141,000 | -4.7% | 13,450 | -19.9% | 0.03% | -15.6% |
| Q1 2020 | $148,000 | +94.7% | 16,800 | -18.3% | 0.03% | +113.3% |
| Q4 2019 | $76,000 | +43.4% | 20,563 | +46.9% | 0.02% | +50.0% |
| Q3 2019 | $53,000 | -36.1% | 14,000 | +7.7% | 0.01% | -28.6% |
| Q2 2019 | $83,000 | -1.2% | 13,000 | +28.7% | 0.01% | -6.7% |
| Q1 2019 | $84,000 | – | 10,100 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |